Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study
Clinical trial NCT07019272 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07019272
- Sponsor
- Hebei Medical University Fourth Hospital
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-06-30
- Primary completion
- 2029-07-31
- Enrollment
- 170
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.